Intermediate risk prostate cancer: Radiotherapy or ADT?

Findings of a long-term study of men with intermediate-risk prostate cancer reveal that those with unfavourable intermediate-risk cancer have better outcomes after neoadjuvant androgen deprivation therapy (ADT) and brachytherapy than those receiving neoadjuvant radiotherapy and brachytherapy.

Nature